TB-500 Dubai: Research Vial & Thymosin Beta-4 Guide
TB-500 is a synthetic fragment of thymosin beta-4, and the first job in any sourcing check is keeping that distinction straight — the research-vial label is not the same thing as the full native protein. The sections below cover identity, COA verification, and where the evidence stops — research-use framing throughout.
Update History ▾
June 4, 2026: Initial publication, drawing on the Remy TB-500 thymosin beta-4 research profile and peer-reviewed and official sources.
Research-use-only framing applied throughout in line with Remy editorial standards.
TB-500 is a synthetic fragment of thymosin beta-4 (also written TB500), so the verification question comes down to confirming the vial is what the label says and reading its COA — not equating it with the full-length protein or its regulated trials. The common laboratory format is a 10mg lyophilized research vial. The sections below cover identity, COA verification, and where the evidence stops — research-use framing throughout.
Verifying TB-500 identity first
TB-500 is written several ways — you will see it as TB500, as tb 500, and described as a thymosin beta-4 fragment — so anyone researching tb 500 or tb-500 dubai is really asking two questions at once: what is in the vial, and whether it is the synthetic fragment or the full native protein. The sections below cover that identity boundary, how to confirm HPLC purity and compound identity (the substance behind a tb 500 coa), what the published thymosin beta-4 research does and does not establish, and how researchers in Dubai and the UAE can document a vial's provenance.
For the full mechanism and trial dataset, read the TB-500 thymosin beta-4 research overview. This guide adds the surrounding evidence, verification, and compliance context.
Evidence Map and Translation Limits
Thymosin beta-4 is a 43-amino-acid actin-sequestering protein with a large repair-biology literature, while TB-500 in research catalogs is generally discussed as a synthetic Tβ4-derived fragment rather than the full native protein.[1] Clinical-trial searches around ophthalmic Tβ4 formulations help explain the evidence boundary but do not validate retail research-vial claims.[2]
| Research layer | What the literature supports | What it means for sourcing |
|---|---|---|
| Identity boundary | Full-length thymosin beta-4 and the market TB-500 fragment are not the same molecule and should not be treated as one. | Confirm the record names the fragment plainly and does not borrow full-protein claims. |
| Evidence tier | The actin-binding literature is mechanistic and model-heavy; human clinical work is concentrated in specific regulated formulations. | Treat the human data as early-stage and formulation-specific, not as a basis for any outcome claim. |
| Dubai research intent | A local researcher needs vial size, format, and a verifiable COA route. | Confirm vial size, format, and the HPLC purity line standard in the analytical record. |
Dubai/UAE Reference Record
The table below records the stable material facts researchers ask about when documenting a TB-500 vial in a UAE laboratory.
| Field | Reference record |
|---|---|
| Compound | TB-500 — synthetic thymosin beta-4 (Tβ4) derived fragment |
| Format | 10mg · Lyophilized research vial |
| Purity reference | >99% HPLC line standard for in-vitro research |
| COA route | Archived analytical records are indexed in the COA library, which publishes Janoshik batch reports across the Retatrutide range. |
| Use restriction | For in-vitro laboratory research only. Not for human or veterinary use. |
Provenance Checks for Laboratory Records
For Dubai and UAE laboratories, the cleanest documentation checklist is evidence-light and verification-heavy. Before logging any TB-500 10mg material, confirm:
- The documentation records vial size and format against a stable reference.
- The record states Research Use Only and avoids human-use, veterinary-use, diagnostic, therapeutic, or disease-management claims.
- The record states the >99% HPLC line standard and an identity method (mass spec) for the compound.
- Cold-storage handling and official-contact verification are documented well enough to reduce impersonation and gray-market risk.
That verification workflow runs through the COA library and contact verification. For the analytical methodology behind a purity figure, see the peptide COA and HPLC purity guide.
What This Page Does Not Claim
The research record helps define the compound, but it does not turn an RUO vial into a clinical product. Keep these boundaries in view:
- Avoid injury-recovery or tissue-repair promises for any individual.
- Do not publish protocols, administration instructions, or human-use comparisons.
- Do not state that research TB-500 equals full-length clinical thymosin beta-4 formulations.
Our Research Standards
This guide draws on the Remy TB-500 thymosin beta-4 research profile and peer-reviewed and official sources. No therapeutic, human-use, or veterinary-use claim is made. Read our editorial policy →
TB-500 10mg Research FAQ
What exactly is TB-500, and how does it differ from thymosin beta-4?
TB-500 is a synthetic fragment derived from thymosin beta-4 (Tβ4), a 43-amino-acid actin-sequestering protein. The fragment and the full-length native protein are not the same molecule, and research records for one should not be read as validating the other.
What format is TB-500 supplied in for laboratory research?
The common laboratory format is a 10mg lyophilized research vial held under 2-8°C cold storage and reconstituted with bacteriostatic water for in-vitro work.
What evidence does this TB-500 10mg guide cover?
This article summarizes compound identity, the strongest peer-reviewed evidence anchors, and the limits of translating regulated or preclinical findings to a research-use vial. It is an evidence map, not a clinical-use guide.
Is TB-500 10mg intended for human or veterinary use?
No. TB-500 research material is for in-vitro laboratory research only. It is not for human use, veterinary use, diagnosis, treatment, cure, disease management, or personal-use protocols.
Which page should researchers read next?
Read the TB-500 thymosin beta-4 research overview for the full actin-biology mechanism, and the BPC-157 vs TB-500 comparison for the side-by-side evidence split.
Sources
- Goldstein AL, Hannappel E, Kleinman HK. Thymosin beta4: actin-sequestering protein moonlights to repair injured tissues. Trends in Molecular Medicine. 2005. PMID: 16099219 ↑
- U.S. National Library of Medicine. ClinicalTrials.gov search results for RGN-259 / thymosin beta-4 ophthalmic studies. clinicaltrials.gov ↑
For the archived analytical route, use the COA library. For wider verification methodology, continue to the peptide COA guide and official contact verification.